Suppression of cytomegalovirus-specific CD8⁺T cells by everolimus

References

• Vitko S, Tedesco H, Eris J, et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004;4: 626–635.
   PubMed Web of Science ®Google Scholar
• Platzbecker U, von Bonin M, Goekkurt E, et al. Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial. Biol Blood Marrow Transplant 2009;15:101–108.
   PubMed Web of Science ®Google Scholar
• Junghanss C, Rathsack S, Wacke R, et al. Everolimus in combination with cyclosporin a as pre- and posttransplantation immunosuppressive therapy in nonmyeloablative allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012;18:1061–1068.
   PubMed Web of Science ®Google Scholar
• Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 2009;9:324–337.
   PubMed Web of Science ®Google Scholar
• Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124:471–484.
   PubMed Web of Science ®Google Scholar
• Nashan B, Gaston R, Emery V, et al. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transplantation 2012;93:1075–1085.
   PubMed Web of Science ®Google Scholar
• Araki K, Youngblood B, Ahmed R. The role of mTOR in memory CD8 T-cell differentiation. Immunol Rev 2010;235:234–243.
   PubMed Web of Science ®Google Scholar
• Araki K, Turner AP, Shaffer VO, et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009;460:108–112.
   PubMed Web of Science ®Google Scholar
• Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010;363:2091–2101.
   PubMed Web of Science ®Google Scholar
• Boeckh M, Geballe AP. Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Invest 2011;121:1673–1680.
   PubMed Web of Science ®Google Scholar
• Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002;99:3916–3922.
   PubMed Web of Science ®Google Scholar
• Riddell SR, Greenberg PD. Principles for adoptive T cell therapy of human viral diseases. Annu Rev Immunol 1995;13:545–586.
   PubMed Web of Science ®Google Scholar
• Schmitt A, Tonn T, Busch DH, et al. Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion 2011;51:591–599.
   PubMed Web of Science ®Google Scholar
• Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003;101:407–414.
   PubMed Web of Science ®Google Scholar
• Gamadia LE, Remmerswaal EB, Weel JF, et al. Primary immune responses to human CMV: a critical role for IFN- gamma-producing CD4+ T cells in protection against CMV disease. Blood 2003;101:2686–2692.
   PubMed Web of Science ®Google Scholar
• Widmann T, Sester U, Gartner BC, et al. Levels of CMV specific CD4 T cells are dynamic and correlate with CMV viremia after allogeneic stem cell transplantation. PLoS One 2008;3:e3634.
   Web of Science ®Google Scholar
• McLaughlin-Taylor E, Pande H, Forman SJ, et al. Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J Med Virol 1994;43:103–110.
   PubMed Web of Science ®Google Scholar
• La Rosa C, Longmate J, Lacey SF, et al. Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J Infect Dis 2012;205:1294–1304.
   PubMed Web of Science ®Google Scholar
• Wang X, Schmitt A, Chen B, et al. Streptamer-based selection of WT1-specific CD8+ T cells for specific donor lymphocyte infusions. Exp Hematol 2010;38:1066–1073.
   PubMed Web of Science ®Google Scholar
• Fei F, Yu Y, Schmitt A, et al. Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens. Exp Hematol 2008;36:1297–1308.
   PubMed Web of Science ®Google Scholar
• Xu X, Stockhammer F, Schmitt A, et al. Therapeutical doses of temozolomide do not impair the function of dendritic cells and CD8+ T cells. Int J Oncol 2012;40:764–772.
   PubMed Web of Science ®Google Scholar
• Guillaume P, Dojcinovic D, Luescher IF. Soluble MHC-peptide complexes: tools for the monitoring of T cell responses in clinical trials and basic research. Cancer Immun 2009;9:7.
   PubMedGoogle Scholar
• Jung T, Schauer U, Heusser C, et al. Detection of intracellular cytokines by flow cytometry. J Immunol Methods 1993; 159:197–207.
   PubMed Web of Science ®Google Scholar
• Wolfl M, Kuball J, Ho WY, et al. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood 2007;110:201–210.
   PubMed Web of Science ®Google Scholar
• Wehler TC, Nonn M, Brandt B, et al. Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines. Blood 2007;109: 365–373.
   PubMed Web of Science ®Google Scholar
• Freiburg UH. Safety study of calcineurin inhibitor free GvHD prophylaxis in allogeneic stem cell transplantation [Internet]. Bethesda, MD: National Library of Medicine; 2000. Available from: www.clinicaltrials.gov/ct2/show/NCT00856505;NLMIdentifier:NCT00856505
   Google Scholar
• Sonpavde G, Choueiri TK, Escudier B, et al. Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?. Eur Urol 2012;61:307–316.
   PubMed Web of Science ®Google Scholar
• Keller F, Wiesner S, Bunjes D, et al. Safety and efficacy of everolimus after kidney and hematopoietic stem cell transplantation. Ann Transplant 2012;17:52–58.
   PubMed Web of Science ®Google Scholar
• Havenith SH, Yong SL, van Donselaar-van der Pant KA, et al. Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine- or mycophenolate-treated patients. Transplantation 2013;95:184–191.
   PubMed Web of Science ®Google Scholar
• Nashan B. Review of the proliferation inhibitor everolimus. Expert Opin Investig Drugs 2002;11:1845–1857.
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Kaplan B, Tedesco Silva H, et al. Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation 2002;73:920–925.
   PubMed Web of Science ®Google Scholar